Literature DB >> 12816629

Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer?

Elena J Ladas1, Kara M Kelly.   

Abstract

The use of complementary and alternative medicine (CAM) is common among patients with cancer. Many of these patients use CAM therapies to decrease the risk of late effects that are sometimes associated with cancer therapy. Certain classes of effective anticancer agents can induce short- and long-term toxicity to the liver. Currently, there are no safer alternatives to these medications. Milk thistle (Silybum marianum) is a botanical that may be useful in the prevention or treatment of liver dysfunction in patients undergoing anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816629     DOI: 10.1089/107555303765551633

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  8 in total

1.  Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.

Authors:  Manjinder Kaur; Balaiya Velmurugan; Alpna Tyagi; Gagan Deep; Suchitra Katiyar; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

2.  Add-On therapy with Chinese herb medicine Bo-Er-Ning capsule (BENC) improves outcomes of gastric cancer patients: a randomized clinical trial followed with bioinformatics-assisted mechanism study.

Authors:  Boyu Pan; Jingyuan Zang; Jie He; Zhen Wang; Liren Liu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

3.  Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules.

Authors:  Balaiya Velmurugan; Subhash Chander Gangar; Manjinder Kaur; Alpna Tyagi; Gagan Deep; Rajesh Agarwal
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

4.  Effects and mechanisms of silibinin on human hepatoma cell lines.

Authors:  John-J Lah; Wei Cui; Ke-Qin Hu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

5.  An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.

Authors:  Hao-Jie Zhu; Bryan J Brinda; Kenneth D Chavin; Hilary J Bernstein; Kennerly S Patrick; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2013-07-08       Impact factor: 3.579

Review 6.  Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Zongguo Yang; Xian Liao; Yunfei Lu; Qingnian Xu; Bozong Tang; Xiaorong Chen; Yongchun Yu
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-07       Impact factor: 2.629

7.  CAM practitioners in the Australian health workforce: an underutilized resource.

Authors:  Sandra Grace
Journal:  BMC Complement Altern Med       Date:  2012-11-02       Impact factor: 3.659

8.  Effect of silibinin in reducing inflammatory pathways in in vitro and in vivo models of infection-induced preterm birth.

Authors:  Ratana Lim; Carrington J Morwood; Gillian Barker; Martha Lappas
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.